Evidence map›Paper›PMID 41283970›Full record

ArticleHuman cell2025

CDC6 promotes the development and progression of clear cell renal cell carcinoma via upregulating RRM2.

Tianpeng Xie, Zanxuan Deng, Youping Ding, Peng Peng, Pan Rao, Yanqun Huang, Lizhen Li, Gaode Zou, Xiaofeng Zou, Mingfeng Xiang

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tianpeng XieDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Institute of Urology, Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China.ORCID http://orcid.org/0000-0001-5038-3677
Zanxuan DengThe First Clinical College, Gannan Medical University, Institute of Urology, Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China.
Youping DingMedical Big Data Center, The First Affiliated Hospital of Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China.
Peng PengThe First Clinical College, Gannan Medical University, Institute of Urology, Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China.
Pan RaoThe First Clinical College, Gannan Medical University, Institute of Urology, Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China.
Yanqun HuangSchool of Inter-Cultural Studies, Jiangxi Normal University, No.437, West Beijing Road, East Lake District, Nanchang, 330022, Jiangxi Province, China.
Lizhen LiThe Second Clinical College, Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang University, No.1, Mingde Road, East Lake District, Nanchang, 310006, Jiangxi Province, China.
Gaode ZouDepartment of Urology, The Second Affiliated Hospital of Nanchang University, No.1, Mingde Road, East Lake District, Nanchang, 310006, Jiangxi Province, China.
Xiaofeng ZouDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Institute of Urology, Gannan Medical University, No.128, Jinling West Road, Economic and Technological Development District, Ganzhou, 341000, Jiangxi Province, China. gyfyzouxf@126.com.
Mingfeng XiangDepartment of Urology, The Second Affiliated Hospital of Nanchang University, No.1, Mingde Road, East Lake District, Nanchang, 310006, Jiangxi Province, China. xmf6688@163.com.ORCID http://orcid.org/0000-0002-2594-2235

Funding

The Doctoral Research Start-up Fund from the First Affiliated Hospital of Gannan Medical University QD073The Guiding Science and Technology Plan Project from the Science and Technology Bureau of Ganzhou City GZ2023ZSF097The Key Research and Development Plan from the Science and Technology Department of Jiangxi Province 20203BBGL73181The Key Research and Development Plan Project from the Science and Technology Bureau of Ganzhou City 2023LNS36910The Science and Technology Research Project from the Education Department of Jiangxi Province GJJ190820
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and exploration of its molecular mechanism benefits for developing more effective molecular targeted drugs. CDC6 has been found to be highly expressed in a variety of malignancies and plays oncogenic role; however, its function in ccRCC has not been elucidated. In this work, immunohistochemical (IHC) staining was used to detect protein expression of genes in clinical tissues. qPCR and WB were used for expression detection of mRNA and protein levels in cells. The Celigo assay, plate cloning assay, flow cytometry, and wound-healing/Transwell assays were used to detect cell proliferation, colony formation, apoptosis, and migration, respectively. A subcutaneous xenograft model in nude mice was used to verify the function of CDC6 in vivo. The results of clinical sample-related detection as well as analysis showed that CDC6 was highly expressed in ccRCC and was significantly associated with higher tumor malignancy as well as worse patients' prognosis. Knockdown of CDC6 in ccRCC cells significantly inhibited cell proliferation and migration while promoting apoptosis, and inhibited in vivo growth of transplanted tumors in animal models. Mechanistically, RRM2 is identified as a potential downstream effector molecule that has co-expression characteristics with CDC6 and whose expression levels are regulated by it. More importantly, RRM2 knockdown mediated tumor suppression could partially reversed CDC6 overexpression induced tumor promotion. This study identified CDC6/RRM2 axis as a potential target for development of novel targeted therapy for ccRCC treatment.

Indexed as

Carcinoma, Renal CellCell Cycle ProteinsGene ExpressionKidney NeoplasmsNuclear ProteinsRibonucleoside Diphosphate ReductaseUp-RegulationAnimalsApoptosisCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceMice, NudeCDC6 protein, humanCell Cycle ProteinsNuclear ProteinsRibonucleoside Diphosphate Reductaseribonucleotide reductase M2CDC6Clear cell renal cell carcinomaMolecular mechanismTumor developmentTumor promotor

Identifiers

PMID41283970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.